Scriptaid

• CAS Number:

  287383-59-9

• UNSPSC Description:

  Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.

• Target Antigen:

  Apoptosis; Autophagy; HDAC; Influenza Virus

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Scriptaid.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(NO)CCCCCN(C(C1=CC=CC2=CC=CC3=C12)=O)C3=O

• Molecular Weight:

  326.35

• References & Citations:

  [1]Keen JC, et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003 Oct;81(3):177-86.|[2]Strobl JS, et al. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. J Parasitol. 2007 Jun;93(3):694-700.|[3]Janaki Ramaiah M, et al. Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects. Gene. 2017 Sep 5;627:379-386.|[4]Ghosh SK, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012 Jan 26;119(4):1008-17.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported